Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival

Frederike G I van Vilsteren, Edwina S. Baskin-Bey, David M. Nagorney, Schuyler O. Sanderson, Walter K Kremers, Charles B. Rosen, Gregory James Gores, Timothy James Hobday

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Liver transplantation for gastroenteropancreatic neuroendocrine cancer (GEP) is controversial. The aim of this study was to assess patient outcomes after liver transplantation for hepatic metastases from GEP. Medical records of patients who underwent liver transplantation for GEP were reviewed. Immunohistochemistry for assessing the Ki67 proliferation index was performed on explanted liver tissue. Nineteen patients who underwent liver transplantation had a mean follow-up of 22 months with a range of 0 to 84 months. There was 1 intraoperative death, and 3 patients had disease recurrence after liver transplantation leading to death in 1 patient. Overall estimated 1-year survival for 17 patients included in the treatment protocol (mean follow-up, 15 months) was 87% with an estimated 1-year recurrence-free rate (conditional on survival) of 77%. Three of 11 patients with pancreatic islet cell GEP developed disease recurrence, whereas all 8 patients with carcinoid GEP remain free of disease. Analysis of the Ki67 proliferation index in 18 patients did not differentiate those with recurrence from those without disease recurrence. In conclusion, liver transplantation for patients with hepatic metastases from GEP is a viable therapeutic option in highly selected patients.

Original languageEnglish (US)
Pages (from-to)448-456
Number of pages9
JournalLiver Transplantation
Volume12
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Liver Transplantation
Patient Selection
Survival
Neoplasms
Recurrence
Islets of Langerhans
Liver
Neoplasm Metastasis
Carcinoid Tumor
Clinical Protocols
Medical Records
Immunohistochemistry

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Liver transplantation for gastroenteropancreatic neuroendocrine cancers : Defining selection criteria to improve survival. / van Vilsteren, Frederike G I; Baskin-Bey, Edwina S.; Nagorney, David M.; Sanderson, Schuyler O.; Kremers, Walter K; Rosen, Charles B.; Gores, Gregory James; Hobday, Timothy James.

In: Liver Transplantation, Vol. 12, No. 3, 03.2006, p. 448-456.

Research output: Contribution to journalArticle

van Vilsteren, Frederike G I ; Baskin-Bey, Edwina S. ; Nagorney, David M. ; Sanderson, Schuyler O. ; Kremers, Walter K ; Rosen, Charles B. ; Gores, Gregory James ; Hobday, Timothy James. / Liver transplantation for gastroenteropancreatic neuroendocrine cancers : Defining selection criteria to improve survival. In: Liver Transplantation. 2006 ; Vol. 12, No. 3. pp. 448-456.
@article{fb11f808c08c4e1980ea0296c3c37865,
title = "Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival",
abstract = "Liver transplantation for gastroenteropancreatic neuroendocrine cancer (GEP) is controversial. The aim of this study was to assess patient outcomes after liver transplantation for hepatic metastases from GEP. Medical records of patients who underwent liver transplantation for GEP were reviewed. Immunohistochemistry for assessing the Ki67 proliferation index was performed on explanted liver tissue. Nineteen patients who underwent liver transplantation had a mean follow-up of 22 months with a range of 0 to 84 months. There was 1 intraoperative death, and 3 patients had disease recurrence after liver transplantation leading to death in 1 patient. Overall estimated 1-year survival for 17 patients included in the treatment protocol (mean follow-up, 15 months) was 87{\%} with an estimated 1-year recurrence-free rate (conditional on survival) of 77{\%}. Three of 11 patients with pancreatic islet cell GEP developed disease recurrence, whereas all 8 patients with carcinoid GEP remain free of disease. Analysis of the Ki67 proliferation index in 18 patients did not differentiate those with recurrence from those without disease recurrence. In conclusion, liver transplantation for patients with hepatic metastases from GEP is a viable therapeutic option in highly selected patients.",
author = "{van Vilsteren}, {Frederike G I} and Baskin-Bey, {Edwina S.} and Nagorney, {David M.} and Sanderson, {Schuyler O.} and Kremers, {Walter K} and Rosen, {Charles B.} and Gores, {Gregory James} and Hobday, {Timothy James}",
year = "2006",
month = "3",
doi = "10.1002/lt.20702",
language = "English (US)",
volume = "12",
pages = "448--456",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Liver transplantation for gastroenteropancreatic neuroendocrine cancers

T2 - Defining selection criteria to improve survival

AU - van Vilsteren, Frederike G I

AU - Baskin-Bey, Edwina S.

AU - Nagorney, David M.

AU - Sanderson, Schuyler O.

AU - Kremers, Walter K

AU - Rosen, Charles B.

AU - Gores, Gregory James

AU - Hobday, Timothy James

PY - 2006/3

Y1 - 2006/3

N2 - Liver transplantation for gastroenteropancreatic neuroendocrine cancer (GEP) is controversial. The aim of this study was to assess patient outcomes after liver transplantation for hepatic metastases from GEP. Medical records of patients who underwent liver transplantation for GEP were reviewed. Immunohistochemistry for assessing the Ki67 proliferation index was performed on explanted liver tissue. Nineteen patients who underwent liver transplantation had a mean follow-up of 22 months with a range of 0 to 84 months. There was 1 intraoperative death, and 3 patients had disease recurrence after liver transplantation leading to death in 1 patient. Overall estimated 1-year survival for 17 patients included in the treatment protocol (mean follow-up, 15 months) was 87% with an estimated 1-year recurrence-free rate (conditional on survival) of 77%. Three of 11 patients with pancreatic islet cell GEP developed disease recurrence, whereas all 8 patients with carcinoid GEP remain free of disease. Analysis of the Ki67 proliferation index in 18 patients did not differentiate those with recurrence from those without disease recurrence. In conclusion, liver transplantation for patients with hepatic metastases from GEP is a viable therapeutic option in highly selected patients.

AB - Liver transplantation for gastroenteropancreatic neuroendocrine cancer (GEP) is controversial. The aim of this study was to assess patient outcomes after liver transplantation for hepatic metastases from GEP. Medical records of patients who underwent liver transplantation for GEP were reviewed. Immunohistochemistry for assessing the Ki67 proliferation index was performed on explanted liver tissue. Nineteen patients who underwent liver transplantation had a mean follow-up of 22 months with a range of 0 to 84 months. There was 1 intraoperative death, and 3 patients had disease recurrence after liver transplantation leading to death in 1 patient. Overall estimated 1-year survival for 17 patients included in the treatment protocol (mean follow-up, 15 months) was 87% with an estimated 1-year recurrence-free rate (conditional on survival) of 77%. Three of 11 patients with pancreatic islet cell GEP developed disease recurrence, whereas all 8 patients with carcinoid GEP remain free of disease. Analysis of the Ki67 proliferation index in 18 patients did not differentiate those with recurrence from those without disease recurrence. In conclusion, liver transplantation for patients with hepatic metastases from GEP is a viable therapeutic option in highly selected patients.

UR - http://www.scopus.com/inward/record.url?scp=33645275187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645275187&partnerID=8YFLogxK

U2 - 10.1002/lt.20702

DO - 10.1002/lt.20702

M3 - Article

C2 - 16498656

AN - SCOPUS:33645275187

VL - 12

SP - 448

EP - 456

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 3

ER -